Clinical Trial Update: Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data

View source ↗

Summary

Clinical trial update analyzing long-term safety of Danicopan as add-on therapy in paroxysmal nocturnal hemoglobinuria using IPIG-Registry data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Danicopan (danicopan)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH | Status: ACTIVE_NOT_RECRUITING